赛诺菲心血管双子星获批：创新BD加速全球新药物首发

Core Insights - Sanofi is demonstrating its commitment to making China a primary market for global innovative drugs, with two cardiovascular drugs approved in late 2025 and early 2026, showcasing its innovative business development model [1][2][3] Group 1: Drug Approvals and Innovations - Sanofi's cardiovascular drugs, Aficamten (brand name: Xing Shuping) and Plerixafor (brand name: Rui Dapu), have been approved in China, marking significant advancements in treatment options for hypertrophic cardiomyopathy and familial chylomicronemia syndrome [1][2][4] - Aficamten is approved for treating obstructive hypertrophic cardiomyopathy in adults, significantly improving exercise capacity and symptoms, with clinical data showing a reduction in left ventricular outflow tract gradient by 50 mmHg over 24 weeks [6][7][8] - Plerixafor is the first targeted therapy for managing triglyceride levels in patients with familial chylomicronemia syndrome, showing an 80% reduction in triglyceride levels after 10 months of treatment [10][11][12] Group 2: Business Development Strategy - Sanofi's innovative business development (BD) model allows it to identify and commercialize promising local drug candidates, with a focus on first-in-class and best-in-class therapies [15][17][18] - The company has gained autonomy in decision-making for drug pipeline acquisitions in China, reflecting its confidence in the local market and its unique disease profile [16][19] - Sanofi's strategic focus on cardiovascular diseases aligns with China's aging population and the increasing prevalence of cardiovascular conditions, positioning the company to meet significant unmet medical needs [20][21] Group 3: Market Position and Future Outlook - By 2025, Sanofi aims to introduce 25 innovative products in China, having already exceeded this target with 34 approvals from 2020 to 2025, including 7 in 2025 alone [22][23] - The company is committed to long-term investments in China, enhancing local R&D and production capabilities while actively participating in health insurance negotiations to improve drug accessibility [21][23]